Skip to main content

Invitae Corporation (NVTA)

NYSE: NVTA · IEX Real-Time Price · USD
27.95
-0.04 (-0.14%)
After-hours:Oct 22, 2021 7:59 PM EDT
27.99
-0.23 (-0.82%)
At close: Oct 22, 4:00 PM
Market Cap6.08B
Revenue (ttm)389.09M
Net Income (ttm)-312.95M
Shares Out204.11M
EPS (ttm)-1.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,131,241
Open28.06
Previous Close28.22
Day's Range27.67 - 28.72
52-Week Range24.16 - 61.59
Beta1.83
AnalystsBuy
Price Target40.44 (+44.5%)
Est. Earnings DateNov 4, 2021

About NVTA

Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. It has a collaboration with Pacific Biosciences of California, Inc. to develop a production-scale high...

IndustryBiotechnology
IPO DateFeb 12, 2015
Employees2,600
Stock ExchangeNYSE
Ticker SymbolNVTA
Full Company Profile

Financial Performance

In 2020, NVTA's revenue was $279.60 million, an increase of 28.95% compared to the previous year's $216.82 million. Losses were -$602.17 million, 148.9% more than in 2019.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NVTA stock is "Buy." The 12-month stock price forecast is 40.44, which is an increase of 44.48% from the latest price.

Price Target
$40.44
(44.48% upside)
Analyst Consensus: Buy

News

Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 Intern...

SAN FRANCISCO, Oct. 22, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), University College London (UCL), and the Francis Crick Institute today announced new data from their TRACERx lung cancer research colla...

22 hours ago - PRNewsWire

If I Could Only Own 1 Healthcare Stock, This Is What It Would Be

Investing gets simple if you have to put all of your eggs in one basket.

1 day ago - The Motley Fool

Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients

BOSTON--(BUSINESS WIRE)-- #breastcancer--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae C...

1 week ago - Business Wire

3 Growth Stocks Wall Street Thinks Could Rise 50% or More

Analyst estimates suggest these stocks can deliver eye-popping gains once the rest of the stock market views them in the same light.

Other symbols:RNLXSOFI
2 weeks ago - The Motley Fool

Can This Stock Grow Despite a COVID Testing Decline?

Fulgent has capitalized on COVID-19 testing, but even though this segment of its business might slow, there are plenty of reasons to own the company.

Other symbols:FLGT
2 weeks ago - The Motley Fool

3 Sinking Stocks Cathie Wood Keeps Buying Anyway

ARK Invest's founder and CEO isn't shy about averaging down on her favorite growth stocks.

Other symbols:MASSSGFY
2 weeks ago - The Motley Fool

New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Pati...

SAN FRANCISCO, Sept. 25, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes ...

3 weeks ago - PRNewsWire

Cathie Wood Goes Bargain Shopping: 3 Sinking Stocks She Keeps Buying

The CEO of ARK Invest is averaging down on these compelling life-science stocks.

Other symbols:ARKKPSNL
1 month ago - The Motley Fool

Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought

All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.

Other symbols:CRSPPSNL
1 month ago - The Motley Fool

As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares?

On Tuesday, Invitae Corp (NYSE:NVTA) shares edged slightly lower after announcing the purchase of health tech company Ciitizen in a cash and stock deal worth $325 million. The company will pay $125 mill...

1 month ago - Invezz

Invitae Strengthens Health Data Platform With Ciitizen Acquisition

Invitae Corp (NYSE: NVTA) has agreed to acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect their genomic and clinical information. Ci...

1 month ago - Benzinga

Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and...

SAN FRANCISCO, Sept. 7, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric c...

1 month ago - PRNewsWire

Invitae to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 1, 2021 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a virtual fire...

1 month ago - PRNewsWire

Ron Muhlenkamp's Firm Goes 1 for 1 in 2nd Quarter

Muhlenkamp & Co. Inc., the investment firm founded by Ronald Muhlenkamp (Trades, Portfolio), released its portfolio for the second quarter earlier this month.

Other symbols:BMYCCJEQCMTZ
1 month ago - GuruFocus

Cathie Wood Stocks: What Names Is ARK Invest CEO Buying Now?

Cathie Wood continues to pick up stocks through her ARK Invest ETFs and we're taking a look at some of their top investments for Tuesday. The post Cathie Wood Stocks: What Names Is ARK Invest CEO Buying...

2 months ago - InvestorPlace

Invitae to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

SAN FRANCISCO, Aug. 9, 2021 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a fireside chat...

2 months ago - PRNewsWire

Why Did Invitae Stock Fall 17% in July?

This genetic testing innovator slumped along with other genomics stocks last month.

2 months ago - The Motley Fool

Why Invitae Stock Is Climbing Today

Accelerating growth is giving investors more confidence in the genetic testing company's long-term prospects.

2 months ago - The Motley Fool

Invitae Stock Jumps As Higher Test Volume More Than Doubles Q2 Topline, Raises FY21 Sales Outlook

Invitae Corporation (NYSE: NVTA), after the close of the market on Tuesday, reported its second-quarter revenues of $116.3 million, +152% Y/Y, exceeding the consensus Wall Street estimate of $108.3 mill...

2 months ago - Benzinga

Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of -30.77% and 6.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Invitae Reports $116.3 Million in Revenue Driven by 287,000 in Billable Volume in Second Quarter of 2021

SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced preliminary financial and operating results for the second quarter ended...

2 months ago - PRNewsWire

Will Invitae (NVTA) Report Negative Earnings Next Week? What You Should Know

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Volpara Collaborates With Invitae Corporation, Leading Genetics Company

SEATTLE, July 22, 2021 /PRNewswire/ -- Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an...

3 months ago - PRNewsWire

Invitae to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

SAN FRANCISCO, July 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2021 financial results on Tuesda...

3 months ago - PRNewsWire

3 Little Known AI Stocks for the Future

With the global release of 5G connectivity, machine learning has become more of a secular trend than ever before.

Other symbols:AILTRN
3 months ago - The Dog of Wall Street